.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Citi
QuintilesIMS
Chinese Patent Office
Merck
Medtronic
Colorcon
Accenture
Federal Trade Commission
AstraZeneca

Generated: November 21, 2017

DrugPatentWatch Database Preview

ULTANE Drug Profile

« Back to Dashboard

What is the patent landscape for Ultane, and what generic Ultane alternatives are available?

Ultane is a drug marketed by Abbvie and is included in one NDA. There are four patents protecting this drug.

This drug has ninety-seven patent family members in thirty-seven countries.

The generic ingredient in ULTANE is sevoflurane. There are five drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the sevoflurane profile page.

Pharmacology for ULTANE

Drug ClassGeneral Anesthetic
Physiological EffectGeneral Anesthesia
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
ULTANE
sevoflurane
LIQUID;INHALATION020478-001Jun 7, 1995ANRXYesYes► Subscribe► SubscribeY► Subscribe
Abbvie
ULTANE
sevoflurane
LIQUID;INHALATION020478-001Jun 7, 1995ANRXYesYes► Subscribe► SubscribeY► Subscribe
Abbvie
ULTANE
sevoflurane
LIQUID;INHALATION020478-001Jun 7, 1995ANRXYesYes► Subscribe► SubscribeY► Subscribe
Abbvie
ULTANE
sevoflurane
LIQUID;INHALATION020478-001Jun 7, 1995ANRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ULTANE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie
ULTANE
sevoflurane
LIQUID;INHALATION020478-001Jun 7, 1995► Subscribe► Subscribe
Abbvie
ULTANE
sevoflurane
LIQUID;INHALATION020478-001Jun 7, 1995► Subscribe► Subscribe
Abbvie
ULTANE
sevoflurane
LIQUID;INHALATION020478-001Jun 7, 1995► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ULTANE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,677,492 Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid► Subscribe
6,558,679 Container for an inhalation anesthetic► Subscribe
6,162,443 Container for an inhalation anesthetic► Subscribe
6,083,514 Polymethylpentene container for an inhalation anesthetic► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ULTANE

Country Document Number Estimated Expiration
Colombia4920220► Subscribe
Austria237295► Subscribe
Hungary0101270► Subscribe
Czech Republic295380► Subscribe
Japan2006143742► Subscribe
South Africa9800418► Subscribe
Slovakia10462000► Subscribe
Austria320798► Subscribe
Australia2110999► Subscribe
Greece3036190► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Accenture
UBS
Argus Health
Dow
Express Scripts
Healthtrust
Daiichi Sankyo
Colorcon
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot